Kala Bio Inc (KALA)
6.36
+0.18
(+2.91%)
USD |
NASDAQ |
Apr 26, 12:52
Kala Bio Cash from Financing (TTM): 8.506M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 8.506M |
September 30, 2023 | 37.76M |
June 30, 2023 | -2.155M |
March 31, 2023 | -5.238M |
December 31, 2022 | -7.942M |
September 30, 2022 | -39.57M |
June 30, 2022 | 1.534M |
March 31, 2022 | 7.393M |
December 31, 2021 | 42.55M |
September 30, 2021 | 63.12M |
June 30, 2021 | 62.63M |
March 31, 2021 | 64.76M |
December 31, 2020 | 160.63M |
September 30, 2020 | 146.20M |
June 30, 2020 | 148.12M |
Date | Value |
---|---|
March 31, 2020 | 140.13M |
December 31, 2019 | 8.982M |
September 30, 2019 | 125.60M |
June 30, 2019 | 122.98M |
March 31, 2019 | 123.04M |
December 31, 2018 | 124.10M |
September 30, 2018 | 0.552M |
June 30, 2018 | 105.62M |
March 31, 2018 | 104.80M |
December 31, 2017 | 103.70M |
September 30, 2017 | 105.31M |
June 30, 2017 | -0.808M |
March 31, 2017 | 66.92M |
December 31, 2016 | 67.21M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-39.57M
Minimum
Sep 2022
160.63M
Maximum
Dec 2020
57.16M
Average
42.55M
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
CEL-SCI Corp | 8.678M |
AIM ImmunoTech Inc | 0.485M |
IGC Pharma Inc | 2.856M |
NovaBay Pharmaceuticals Inc | 1.91M |
Protalix BioTherapeutics Inc | 24.67M |